Exploration of the Syndrome and Treatment Law and Mechanism of Formulated Preparations Containing Shengshigao(Gypsum Crudum)in the Pharmacopoeia of the People's Republic of China Based on the Traditional Chinese Medicine Inheritance Assistance Platform and
Objective:To study the syndrome and treatment law and mechanism of formulated preparations containing Shengshigao(Gypsum Crudum)in the 2020 edition of the Pharmacopoeia of the People's Republic of China.Method:The formulated preparations meeting the inclusion and exclusion criteria were recorded into the traditional Chinese medicine inheritance assistance platform(TCMIAP).Based on the frequency statistics,association rules and clustering algorithm functions of the TCMIAP,the compatibility principle,prescription formation law and new prescription combination of the formulated preparations containing Shengshigao(Gypsum Crudum)were analyzed,and the core drugs were extracted.At the same time,the network pharmacology method was used to study the mechanism of gypsum action in the main traditional Chinese medcine(TCM)diseases screened in the study of syndrome and treatment.Result:A total of 50 formulated preparations containing gypsum were ultimately included,involving 24 TCM diseases such as pulmonary cough,pneumonia and asthma,and common cold,and 22 suitable syndrome type such as phlegm heat obstructing the lung,wind heat in the lung meridian,and heat toxin internal accumulation.There were 170 traditional Chinese Medicine such as Shengshigao(Gypsum Crudum),Gancao(Glycyrrhizae Radix),Huangqin(Scutellariae Radix),Xingren(Armeniacae Semen),and Mahuang(Ephedrae Herba)were also included.At the same time,4 core drug pairs such as"Shengshigao(Gypsum Crudum)-Gancao(Glycyrrhizae Radix)"and"Shengshigao(Gypsum Crudum)-Huangqin(Scutellariae Radix)",7 new prescription combinations such as"Shengshigao(Gypsum Crudum)-Wuweizi(Schisandrae Fructus)-Zhishi(Aurantii Fructus Immaturus)-Jiegeng(Platycodonis Radix)",and 6 core drug groups such as"Shengshigao(Gypsum Crudum),Mahuang(Ephedrae Herba),Gancao(Glycyrrhizae Radix),Xingren(Armeniacae Semen),Huangqin(Scutellariae Radix),Jiegeng(Platycodonis Radix),and Chenpi(Citri Reticulatae Pericarpium)"were extracted.Moreover,18 intersection targets of"Shengshigao(Gypsum Crudum)-major TCM diseases"such as ALB,IL-IB and 1L-6 were screened,and 3 major signaling pathways such as TNF,LL-17 and HIF-1 were obtained.Conclusion:The formulated preparations containing Shengshigao(Gypsum Crudum)in the 2020 edition of the Pharmacopoeia of the People's Republic of China was based on Maxingshigan Tang(麻杏石甘汤),and its mechanism might be related to the inhibition of signaling pathways such as TNF,IL-17,and HIF-1 by Shengshigao(Gypsum Crudum),down-regulating the inflammatory response process,and reducing the release of pro-inflammatory factors.
Shengshigao(Gypsum Crudum)formulated preparationstraditional Chinese medicine inheri-tance auxiliary platformnetwork pharmacologyPharmacopoeia of the People's Republic of China
万方数据
维普
